VTX-2735 / Ventyx Biosci - LARVOL DELTA

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Zomagen Biosciences Ltd.

New P2 trial • Cardiovascular

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio (GlobeNewswire) - "Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025..."

New P2 trial • P2 data • Inflammation

Explore: A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (clinicaltrials.gov) - P2 | N=7 | Completed | Sponsor: Zomagen Biosciences, Ltd | Recruiting ➔ Completed | Phase classification: P2a ➔ P2 | N=10 ➔ 7 | Trial completion date: Dec 2023 ➔ Mar 2024 | Trial primary completion date: Oct 2023 ➔ Mar 2024

Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Inflammation

Ventyx Biosciences Announces $100 Million Private Placement of Common Stock (GlobeNewswire) - "Ventyx Biosciences, Inc...announced today that it has entered into a stock purchase agreement for the sale of 11,174,000 shares of its common stock at an offering price of $8.95 per share in a private placement to certain qualified institutional buyers and institutional accredited investors. Gross proceeds of the private placement are expected to be approximately $100 million....Ventyx currently intends to use the net proceeds from the proposed private placement, together with existing cash and cash equivalents, to fund the clinical development of VTX3232, VTX2735, VTX002, and the preclinical development of other programs, research activities and working capital and other general corporate purposes."

Financing • CNS Disorders • Immunology • Inflammatory Bowel Disease

Explore: A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (clinicaltrials.gov) - P2a | N=10 | Recruiting | Sponsor: Zomagen Biosciences, Ltd

New P2a trial • Inflammation

Pharmacokinetics, Safety and Pharmacodynamics of VTX2735, A Potent and Selective NLRP3 Inhibitor, In Healthy Adult Volunteers (AAD 2023) - "VTX2735 also reduced high sensitivity CRP levels 50% from baseline. These data support further development of VTX2735."

Clinical • PK/PD data • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Psoriasis • CRP • IL18 • IL1B • LCN2 • NLRP3 • TNFA